Examining the Potential Price Growth of Harvard Bioscience Inc. (HBIO)


Harvard Bioscience Inc.’s recently made public that its Chief Executive Officer Green James W acquired Company’s shares for reported $0.11 million on Aug 17. In the deal valued at $4.38 per share,25,000 shares were bought. As a result of this transaction, Green James W now holds 2,862,679 shares worth roughly $ 12.62 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Green James W bought 20,000 shares, generating $52,000 in total proceeds. Upon buying the shares at $2.60, the Chief Executive Officer now owns 2,886,052 shares.

Before that, EDRICK ALAN I bought 16,192 shares. Harvard Bioscience Inc. shares valued at $42,423 were divested by the Director at a price of $2.62 per share. As a result of the transaction, EDRICK ALAN I now holds 202,485 shares, worth roughly $0.89 million.

The Benchmark Company upgraded its Harvard Bioscience Inc. [HBIO] rating to a Buy from a a Speculative buy in a research note published on Friday, March 10, 2023; the price target was increased to $4 from $3. PT values the company’s stock at a premium of -10.25 to its Friday closing price.

Price Performance Review of HBIO

On Friday, Harvard Bioscience Inc. [NASDAQ:HBIO] saw its stock remained unchanged to $4.41. On the same session, the stock had its day’s lowest price of $4.39, but rose to a high of $4.47. Over the last five days, the stock has gained 2.32%. Harvard Bioscience Inc. shares have risen nearly 59.21% since the year began. Nevertheless, the stocks have risen 33.64% over the past one year. While a 52-week high of $6.29 was reached on 05/02/23, a 52-week low of $1.98 was recorded on 03/08/23. SMA at 50 days reached $4.89, while 200 days put it at $4.07. A total of 82507.0 shares were traded, compared to the trading of 65000.0 shares in the previous session.

Levels Of Support And Resistance For HBIO Stock

The 24-hour chart illustrates a support level at 4.38, which if violated will result in even more drops to 4.34. On the upside, there is a resistance level at 4.46. A further resistance level may holdings at 4.50. The Relative Strength Index (RSI) on the 14-day chart is 45.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 31.48%. Stochastics %K at 73.11% indicates the stock is a holding.

How much short interest is there in Harvard Bioscience Inc.?

A steep rise in short interest was recorded in Harvard Bioscience Inc. stocks on Aug 14, 2023, dropping by 36230.0 shares to a total of 0.98 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 1.02 million shares. There was a decline of -3.68%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 2.39% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.43.

Harvard Bioscience Inc. [HBIO] – Who Are The Largest Shareholders?

In filings from B. Riley Asset Management LLC, it is revealed that the company now owns 3,062,963 shares, or roughly 7.26% of the outstanding HBIO shares. In other words, the investor’s shares have fallen by -345,833 from its previous 13-F filing of 3408796.0. Additionally, Punch & Associates Investment Man decreased -2.87% of its stake after which the total value it holdings stand at $13,311,318, while Harvey Partners LLC reduced -6.96% of its stake to hold $11.74 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 1,544,721 shares of Harvard Bioscience Inc., while AMH Equity Ltd. bought 158,794 shares. At present, The Vanguard Group, Inc. is holding 1,887,183 shares valued at $8.78 million. Dimensional Fund Advisors LP owned 1,817,629 shares of the company at the time of its most recent 13F filing, worth $8.45 million.

According to FactSet, Harvard Bioscience Inc.’s share price will average $6.42 in the next year, based on opinions of analysts polled by the firm. This is up nearly 58.73 percent from its previous closing price of $4.41. Analysts expect Harvard Bioscience Inc. stock to reach the higher price of $7.00, while the lowest price estimate is $5.25. However, 3 analysts have rated HBIO stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here